Table 2.
Cross-Reactivity Results for Non-COVID-19 Mixed Infection Prepandemic Group
| Antibodies Against | Euro S1-IgA | Euro S1-IgG | Euro NCP-IgG | GenScript sVNT | Wantai IgM | Wantai Total Ab |
|---|---|---|---|---|---|---|
| SARS-CoV-1 | 1/1 | 1/1 | 1/1 | 1/1 | 1/1 | 1/1 |
| MERS-CoV | 0/9 | 0/9 | 1/9 | 0/9 | 0/9 | 0/9 |
| Seasonal hCoV | 0/5 | 0/5 | 0/5 | 0/4 | 0/2 | 0/2 |
| Mycoplasma | 1/4 | 1/4 | 2/4 | 0/4 | 0/2 | 0/2 |
| Parvovirus, parvo/HCV | 0/4 | 0/4 | 0/4 | 0/4 | 0/5 | 0/2 |
| CMV | 1/2 | 1/2 | 1/2 | 0/2 | 0/7 | 0/5 |
| Dengue | 1/5 | 0/5 | 0/5 | 0/5 | 0/6 | 0/7 |
| EBV | 0 | 0 | 0 | 0 | 0/4 | 0/4 |
| Flu A, adenovirus | 0 | 0 | 0 | 0 | 0/1 | 0/1 |
| Hep A, B, C, syphilis, HIV | 0 | 0 | 0 | 0 | 0/6 | 0/6 |
| Total | 4/30 | 3/30 | 5/30 | 1/30 | 1/30 | 1/36 |
| % positive | 13.3% | 10.0% | 16.7% | 3.3% | 3.3% | 2.8% |
Abbreviations: Ab, antibody; CMV, cytomegalovirus; EBV, Epstein-Barr virus; Euro, Euroimmun; Flu A, influenza A virus; HCV, hepatitis C virus; Hep, hepatitis; Ig, immunoglobulin; MERS-CoV, Middle East respiratory syndrome; NCP, nucleocapsid; Parvo, parvovirus; SARS-CoV-1, severe acute respiratory syndrome coronavirus 1.